
Unpacking the ACIP Overhaul: Chaos and Controversy
This edition of Medicine Matters underscores the chaos and controversy at the June 2025 Advisory Committee on Immunization Practices (ACIP) meeting.
What Is ACIP and Why Are ACIP Recommendations So Important?
ACIP was established in 1964, and its charge was to make vaccine recommendations for the entire country. For years, ACIP's collaborative, transparent, and evidence-based process has been trusted by clinicians and helped protect Americans from vaccine-preventable diseases.
ACIP recommendations are directly tied to insurance coverage. ACIP-recommended vaccines on the child and adult immunization schedules have to be covered by Affordable Care Act (ACA)-compliant insurance plans. ACIP also makes recommendations about which vaccines should be included in the Vaccines for Children (VFC) program. VFC ensures every child in America has access to vaccines — even if their parents can't afford them. This program provides vaccines to 50% of children in this country.
I've been a liaison to ACIP for nearly two decades. In those 20 years, during both Republican and Democratic administrations, I've observed ACIP to be the crown jewel of our public health system, preventing hundreds of thousands of hospitalizations and deaths and untold suffering. ACIP has also been a beacon of trust for physicians and the public when it comes to vaccines.
ACIP Overhaul Leads to Controversy at the June Meeting
That crown jewel was blown apart in early June when the new HHS Secretary, Robert F. Kennedy, Jr, removed all 17 ACIP members, claiming — but not explaining — supposed conflicts of interest. Many of Kennedy's eight handpicked replacements have gone on record with preconceived bias against vaccines. One appointee withdrew his name due to financial conflict-of-interest concerns.
For a few days, it seemed "touch-and-go" as to whether the meeting would even happen. Senator Bill Cassidy, the physician who chairs the Senate HELP Committee, was so concerned about the qualifications of this new panel that he wanted the meeting to be delayed.
The draft agenda for June's ACIP meeting, first posted mid-June, was significant in itself for what it did not include. A highly anticipated discussion and vote on HPV vaccines was entirely omitted. The agenda also lacked a vote for COVID vaccines.
On Tuesday, May 27, HHS Secretary Kennedy made an HHS directive and unilaterally removed COVID vaccines from the immunization schedule for healthy children and for pregnant women. He made this announcement on social media. No new evidence was cited to support this decision. Absent from this announcement was any representative from the CDC or ACIP.
A new addition to the ACIP agenda — a thimerosal presentation by Lyn Redwood— was probably the most controversial. Her presentation slides that were originally posted on the ACIP website initially cited a study that didn't exist and did not accurately represent conclusions of other articles that do exist.
A CDC review of the evidence debunked thimerosal myths and refuted Redwood's comments. This CDC review (initially put up on the ACIP website and then abruptly taken down) clarified that all childhood vaccines licensed and recommended in the US have been thimerosal-free since 2001, with the exception of some multidose formulations of flu vaccines. It also explained the evidence does not support an association between thimerosal-containing vaccines and autism spectrum disorder or other neurodevelopmental disorders.
When it came time to vote, the new panel reaffirmed routine annual flu vaccination for everyone 6 months or older. But when additional votes involved thimerosal, all but one member ignored the true scientific evidence. Six of the seven members of the panel voted to remove thimerosal from flu shots for children, pregnant women, and adults. The only one who followed the evidence and voted against this decision was the sole pediatrician on the panel, Dr Cody Meissner. Dr Meissner previously served on the ACIP and explained, "The risk from influenza is so much greater than the nonexistent, as far as we know, risk from thimerosal."
Concerning Comments From ACIP's New Chair
The new chair of the ACIP, Martin Kulldorff, PhD, called for ' a review of long-approved vaccines.' He said ACIP will be taking a look at the cumulative effect of the recommended vaccine schedules, including interaction effects between different vaccines, the total number of vaccines, cumulative amounts of vaccine ingredients, and the relative timing of different vaccines. The current child and adult schedules are evidence-based and have been in place for long periods of time. This type of review could totally upend the child and adult immunization schedules as we know them.
Kulldorff also explained that ACIP will be taking a new look at use of the MMR and varicella vaccine for young children. Further, he announced that a new vaccine work group may look at the need for the universally recommended hepatitis B vaccine dose on the day of birth — a cornerstone of hepatitis B prevention for the entire population. The American Academy of Pediatrics (AAP) has already pushed back on social media, explaining that passing the virus from parent to baby at birth can be deadly.
Medical Organizations Speak Out and Push Back
Meanwhile, organized medicine has gone on the offensive. The AAP showed its disapproval by boycotting the meeting. The American Medical Association (AMA) released a statement that this removal of ACIP's 17 qualified members 'undermines that trust and upends a transparent process that has saved countless lives.' The AMA, along with 78 other medical organizations, also issued an open letter to the public, backing vaccination as the best way to protect against respiratory viruses, including flu, COVID, and RSV, and their potentially serious complications. These organizations called on insurers, hospitals, and public health agencies to ensure these life-saving vaccines remain available to patients without cost-sharing.
Many physicians and other clinicians are looking for alternatives for vaccination guidance now that it seems the CDC can no longer be their "North Star." Michael Osterholm, director of the Center for Infectious Disease Research and Policy at the University of Minnesota, is already launching the Vaccine Integrity Project.
An Unclear Future for Vaccine Policy and Public Health
This is the tragic bottom line: ACIP was put on life support when all 17 of the remarkable physicians, scientists, and vaccine experts were fired for clearly political reasons. This first ACIP meeting since that purge confirmed our worst fears. It gave platform and voice to an unscientific, debunked presentation on the vaccine preservative thimerosal, given by someone who was clearly unqualified and uncredentialed to even address this issue. ACIP is supposed to address vaccine policy that can bring health and happiness — not death and illness — to our country.
America's physicians try to work collaboratively with everyone at these public health agencies to advance the nation's health. But physicians must also stand up for our patients. We must push back on misinformation, medical foolishness, and quackery. Unfortunately, that is the only way to describe that thimerosal presentation and — more importantly — the 6-1 vote that adopted the debunked thimerosal presentation as ACIP policy.
Misinformation is designed to stoke mistrust in vaccines. Mistrust reduces vaccine uptake, and reduced vaccine uptake kills and sickens our patients. We wouldn't be in the midst of a measles outbreak but for vaccine hesitancy.
If this is what we can expect out of the new ACIP, physicians need to get ready for more suffering and death — because that is surely what is coming.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Trade the Warren Buffett Rally in UnitedHealth Stock With This High-Reward, Low-Risk Options Strategy
Early in my professional investing career, I learned that no matter how much you think you know, the market knows more. So while we should always try to assess where a stock or sector is headed, the better way to trade is with a simple framework: Any stock can go up and thus be a source of profits. However, owning each stock comes with different levels of risk, at different times. More News from Barchart Lyft Generates Huge FCF Margins - LYFT Stock Is Too Cheap Hedge Your Bets With This SPY Options Strategy While the VIX is Still Low Option Volatility And Earnings Report For Aug 18 – 22 Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. That's why, when I see a stock like United Healthcare (UNH), I remind myself, and you, that when a stock has been a headline-level bust all year, it sets up two scenarios. The first is that it has giant upside potential, as investors reconsider it. And, second is that it has about as much risk of major loss as it has just demonstrated. UNH's issues started with a horrific public tragedy, and then a self-induced set of behaviors and processes that put it in the crosshairs of regulators. And, in turn, investors. This month, some of those headwinds suddenly reversed, as major investors including Warren Buffett's Berkshire Hathaway (BRK.A) (BRK.B) and David Tepper's Appaloosa Management announced investment positions in the troubled healthcare giant and Dow Jones Industrial Average ($DOWI) member. But UNH is still facing a lot of issues. So, in my world, that means it's time to talk about collaring the stock using options, and pointing to Barchart's very well-organized and time-saving options data for help. UNH Stock Is an Ideal Options Collar Trade Here's why UNH is a great collar setup to me. The stock is way down, what I call a 'dog collar' situation. UNH dove in price with the market in early April, but its potential legal trouble surfaced around the time the S&P 500 Index ($SPX) and other broad market indicators rallied back. The stock has gone from approaching its all-time high in early April, to less than half its $600 high-water mark for 2025. Ah, but then the white knights of Wall Street appeared. And UNH is still a very robust business, a healthcare leader. So this creates a dichotomy of sorts. And increases the chances of a big move in either direction. This is exactly the best scenario for collars, if you are a risk manager like I insist on being. For those who believe that if you 'just buy and hold great stocks' everything will work out, UNH is a cautionary tale. Few, if any, stocks are immune to long stretches in which they do not produce any returns. In the case of UNH, its 12% pop on Friday brought its return for last week above 20%. Impressive. But that only brings it back to where it traded during the middle part of 2020! Risk happens, and it happens fast sometimes. Collaring Stocks Lets You Play Offense and Defense… At the Same Time! Collars are misunderstood by many investors. While they are designed to protect against loss below a certain price threshold over a set period of time, they do not have to represent lost upside potential. Because unless I spend all of my assets on that collar, if it blasts above the call strike price before expiration date, I can buy more stock. Or buy call options. So I'm not missing out on a 'flyer.' I just need to do more work to continue pursuing price growth above the call strike price. As I've written here many times, collaring stocks is hardly a one-size fits all process. Every stock is at least a little different, as are the option contract specifications available. UNH has a very active options market, especially after the events of the past several months. Many traders are trying to turn their beliefs about the stock into profits. I looked out to the second half of 2026, but the pricing was not much better than staying shorter term. So above you see one possibility, going out 6 months to February 2026. There's always a tradeoff an investor needs to accept with collaring stocks. In this example, that tradeoff is on the out-of-pocket cost, around 6%. That's the main 'risk' here, since the put strike price is $300, just below Friday's $304 closing price. So the downside is that cost plus a few dollars a share, or about 8%. For a stock down more than 50%. The upside is out to $380, which is where the stock had one of its 2025 meltdown moments, back in May. That now represents 18% upside before any capping of gains would occur. Risk Management Does Not Have to Mean Sacrificing Returns This is merely one example of what we can do if we step back for a moment and think of what investing is. To me, it is not so much about 'owning great companies,' since markets work differently now. They reward those who use the markets as a tool to pursue profits with high liquidity. And they also reward those who make risk management front and center in their investment decisions. Collaring stocks, especially those in turmoil, can be a very useful, flexible part of that toolbox. On the date of publication, Rob Isbitts did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
20 minutes ago
- Yahoo
Why GoodRx (GDRX) Stock Is Trading Up Today
What Happened? Shares of healthcare tech company GoodRx (NASDAQ:GDRX) jumped 40.2% in the afternoon session after the company announced a collaboration with pharmaceutical giant Novo Nordisk to offer the popular medications Ozempic and Wegovy for $499 per month to eligible self-paying customers. This landmark collaboration makes the popular GLP-1 medications—used for type 2 diabetes (Ozempic) and weight loss (Wegovy)—available at a significantly lower cost to those who lack adequate insurance coverage. According to the announcement, this marks the first time Ozempic has been offered at this self-pay price point. The offer is effective immediately and available through the GoodRx platform at over 70,000 retail pharmacies nationwide. Investors reacted positively, viewing the strategic partnership as a pivotal move that could substantially expand GoodRx's market reach and user base by capitalizing on the high-demand therapeutic category. Is now the time to buy GoodRx? Access our full analysis report here, it's free. What Is The Market Telling Us GoodRx's shares are very volatile and have had 27 moves greater than 5% over the last year. But moves this big are rare even for GoodRx and indicate this news significantly impacted the market's perception of the business. The biggest move we wrote about over the last year was about 2 months ago when the stock gained 5.7% on the news that the major indices rebounded (Nasdaq +1.4%, S&P 500 +1.0%) on hopes the reported ceasefire between Israel and Iran will hold. This de-escalation in a volatile region helped to ease concerns about potential disruptions to global oil supplies, leading to a notable dip in crude oil prices. Additionally, dovish signals from Federal Reserve Chair Jerome Powell in his Congressional testimony, reaffirming a "wait-and-see" approach on interest rates, further calmed markets, improving investors' appetite for stocks and other risk assets. GoodRx is up 12.9% since the beginning of the year, but at $5.15 per share, it is still trading 40.1% below its 52-week high of $8.59 from August 2024. Investors who bought $1,000 worth of GoodRx's shares at the IPO in September 2020 would now be looking at an investment worth $101.96. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
33 minutes ago
- Yahoo
Measles outbreak that sickened more than 700 declared over in Texas
A measles outbreak in Texas that infected more than 700 people has officially been declared over, state health officials announced on Monday. The outbreak was the largest in the state in more than 30 years and led to the deaths of two unvaccinated school-aged children. Health officials declared the outbreak over after more than 42 days without a new case, a cut-off based on the time between when a person is exposed to when they get sick. MORE: Measles cases in US over 4.5 times higher than all of last year In late January, a cluster of cases was reported in western Texas near Gaines County -- near the border with New Mexico -- which had one of the lowest vaccination rates in the state. A total of 762 cases were recorded with more than two-thirds of infections among children, according to the Texas Department of State Health Services (DSHS). Nearly 100 people were hospitalized. Infections spread to other parts of the state as well as New Mexico, where another unvaccinated person died after contracting measles. "I want to highlight the tireless work of the public health professionals across the state who contributed to the containment of one of the most contagious viruses," Dr. Jennifer Shuford, commissioner of the DSHS, said in a press release. "We arrived at this point through a comprehensive outbreak response that included testing, vaccination, disease monitoring and educating the public about measles through awareness campaigns." Texas health officials warned that the state is likely to experience additional cases this year given ongoing outbreaks in other parts of the U.S. and the world. "The end of this outbreak is certainly encouraging, but measles remains one of the most contagious viruses we face, and continued vigilance is critical given ongoing outbreaks both in the U.S. and globally," said Dr. John Brownstein, an epidemiologist and ABC News medical contributor. Nationally, over 1,350 cases of measles have been reported across at least 40 states, according to the Centers for Disease Control and Prevention (CDC). It is the highest number of measles cases seen in the U.S. since 1992. MORE: Amid growing Texas outbreak, how contagious is measles? The virus was declared eliminated by health officials in 2000 after a full year of no continuous spread, but declining vaccination rates have led to a growing number of outbreaks annually, experts say. An estimated 92% of cases nationally this year are unvaccinated or have unknown vaccination status. "Vaccination rates in many communities remain far too low, leaving large pockets of children vulnerable to measles and other preventable diseases -- and that's why we're likely to continue seeing outbreaks," Brownstein said. The 2024-2025 school year had a record number of non-medical vaccine exemptions, with an estimated 286,000 kindergarteners attending school without documentation of receiving the shot that protects against measles, according to CDC data. "Measles isn't happening in isolation -- we're seeing a broader resurgence of vaccine-preventable diseases, from pertussis to polio threats, which underscores the urgent need to maintain high vaccination coverage and public trust in immunization," Brownstein added. The measles, mumps and rubella (MMR) vaccine is recommended for children in the U.S. to receive after their first birthday, followed by a second dose in between ages four and six. Two doses of the vaccine have been shown to be 97% effective against infection. Solve the daily Crossword